Thyroid cancer
Also known as: Thyroid carcinoma, Papillary thyroid carcinoma, Follicular thyroid carcinoma, Medullary thyroid carcinoma, Anaplastic thyroid carcinoma
Thyroid carcinoma comprises various histological subtypes, including differentiated papillary and follicular carcinomas, medullary thyroid cancer, and highly aggressive anaplastic variants. Conventional management is determined by histology, stage, and individual risk, incorporating specialist-led surveillance, surgical resection, radioactive iodine (RAI) therapy, thyroid hormone treatment, radiotherapy, or systemic therapies. Traditional Chinese Medicine (TCM) is restricted to adjunctive symptom management and requires oncologist approval. Current clinical evidence is characterised by heterogeneity and low methodological quality, with unresolved safety concerns regarding herbal interventions; the cited evidence demonstrates no improvement in survival or recurrence rates. Preclinical findings for Polyphyllin II lack clinical translation, and no direct evidence supports the efficacy of acupuncture or the specific formula-point protocols listed.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Strictly adhere to specialist consultations and surveillance protocols. Maintain consistent thyroid hormone replacement therapy and consult a pharmacist regarding the optimal timing for co-administration with other supplements.
- •Maintain optimal nutritional status and hydration. Restrict iodine intake only when clinically indicated for radioactive iodine preparation; avoid kelp and iodine supplements unless specifically prescribed.
- •Undertake gentle ambulation and prescribed cervical or scapular exercises, modulating activity levels according to fatigue and postoperative clinical guidelines.
- •Maintain a systematic log of pain, sleep quality, fatigue, deglutition, and body weight. Seek psychological or peer support services as required.
Cautions & Contraindications
- •Do not use TCM to defer biopsy, indicated surgery, radioactive iodine, systemic treatment or surveillance, or to alter prescribed thyroid hormone. Adjunctive positioning is supported by the reviews; the specific precautions here are clinical safety guidance rather than abstract-tested recommendations.[,]
- •Avoid needling through a thyroid mass, suspicious node, anterior neck treatment field, unhealed incision, infected skin or radiation-damaged tissue. Obtain oncology clearance where blood counts, healing or infection risk are concerns; no acupuncture safety trial is supplied.[,]
- •Do not introduce herbal products during perioperative care, radioactive iodine preparation or systemic treatment without oncology and pharmacist review. The reviews identify unresolved herbal safety risks, not verified compatibility with cancer medicines.[,,]
- •Do not extrapolate polyphyllin II cell and xenograft findings into a recommendation to ingest Paris polyphylla or related products; human benefit and a safe clinical regimen are not established by this study.[]
When to reassess or seek care again
If adjunctive care is approved, review after 2–4 weeks using baseline and follow-up 0–10 fatigue, pain, nausea and sleep scores, together with daily functioning, intake and adverse effects. Stop or modify ineffective care rather than continuing indefinitely. Refer promptly for worsening symptoms, unintended weight loss, new focal pain or persistent palpitations; escalate red flags immediately. Cancer response and surveillance remain specialist responsibilities, not tongue, pulse or symptom-based judgements.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Biomolecules & therapeutics · 2026
- Cancer management and research · 2026
- Oncology reports · 2026
- International journal of general medicine · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
